PRESS RELEASE published on 01/17/2024 at 15:00, 2 years 9 months ago Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform Xenetic Biosciences, Inc. has entered into a Research Funding Agreement and a Material Transfer Agreement with the University of Virginia to advance the development of its systemic DNase program, targeting neutrophil extracellular traps involved in cancer progression. The company believes that the data generated by its research and development collaborations are crucial for unlocking the potential of its DNase technology and driving a clinical path for its lead solid tumor indications. The agreement with UVA provides a significant addition to Xenetic's development capabilities and resources, accelerating development timelines. Dr. Allan Tsung, an internationally recognized surgical oncologist and scientist, will oversee the research conducted under the agreement. Xenetic is working towards its planned first-in-human study to evaluate DNase combined with immune checkpoint inhibitors or chemotherapy. For more information, visit Xenetic Biosciences' website at www.xeneticbio.com. Xenetic Biosciences DNase Program Neutrophil Extracellular Traps Cancer Progression University Of Virginia
PRESS RELEASE published on 11/10/2023 at 14:35, 2 years 11 months ago Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results
PRESS RELEASE published on 10/11/2023 at 15:05, 3 years ago Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference
Published on 11/04/2026 at 23:10, 3 hours 15 minutes ago Ur-Energy Announces Date for Third Quarter 2026 Results and Conference Call and Webcast
Published on 11/04/2026 at 23:00, 3 hours 25 minutes ago Viemed Healthcare Announces Third Quarter 2026 Financial Results
Published on 11/04/2026 at 22:15, 4 hours 10 minutes ago Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity
Published on 11/04/2026 at 22:05, 4 hours 20 minutes ago Stabilis Solutions Announces Third Quarter 2026 Results
Published on 11/05/2026 at 00:02, 2 hours 22 minutes ago EQS-Adhoc: NEXTDC Limited: Response to Share Raid by Goodman Group and Digital Realty
Published on 11/04/2026 at 19:41, 6 hours 43 minutes ago EQS-Adhoc: SNP SE Raises Outlook for the Full Year 2026
Published on 11/04/2026 at 19:25, 6 hours 59 minutes ago Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting
Published on 11/04/2026 at 18:43, 7 hours 41 minutes ago EQS-Adhoc: Deutsche EuroShop refines its revenue forecast and raises its earnings forecast for the 2026 financial year
Published on 11/04/2026 at 18:05, 8 hours 19 minutes ago Redis Expands Redis Iris to Give AI Agents the Memory, Context, and Messaging They Need to get to Production
Published on 11/04/2026 at 18:00, 8 hours 24 minutes ago The Belgian State and Engie Group have agreed to extend the target date for concluding the Heads of Terms until 12 December 2026
Published on 11/04/2026 at 18:00, 8 hours 24 minutes ago L’État belge et le groupe ENGIE ont convenu de se donner un délai supplémentaire jusqu’au 12 décembre 2026 pour la conclusion des Heads of Terms
Published on 11/04/2026 at 17:44, 8 hours 41 minutes ago Aéroports de Paris SA - Information regarding the voting rights and shares as of 31 October 2026
